CPhI Worldwide experienced its most international audience this year, highlighting a number of new trends as well as the overall strength of the pharma industry.
International
As the only platform that connects global pharma companies, it’s no surprise that the majority of the show’s visitors were international. The impressive showing means that the industry looks set for a strong 2019 and across the show’s three days, CPhI Worldwide received more than 103,000 visits.
One of the biggest trends this year was the integration of small and large molecules and CPhI Worldwide, made evident by the inclusion of bioLIVE, the show’s bioprocessing and manufacturing exhibition added this year.
The new exhibition had over 150 sessions dedicated to a range of themes including developments in cell and gene therapies, biosimilars and capacity challenges across the globe, as well as new manufacturing and processing techniques.
The global outlook towards pharma seems to be especially positive, results from CPhI Worldwide’s annual survey show. For the second year running, Germany, Japan and the US emerged as the top-ranked nations for pharmaceutical quality and overall score, with India and China making large strides in raising their overall reputation.
The show’s host nation, Spain also made a significant improvement in regard to international reputation, largely thanks to the country’s biotech hubs in Barcelona and Madrid.
Orhan Caglayan, CPhI brand director said: “The 2018 CPhI Worldwide event showcased the incredible strength of pharma, and we are seeing good growth potential across all sectors from API and finished product to bio, generics and NCEs. But what has been most significant is the internationalisation of partnering; furthermore we see a wider spread of international attendees year-on-year at CPhI Worldwide. Another notable trend and reflected in our content programmes at the event, has been the rise of innovation in the industry, with more new products in development, but also, new technologies that lower overall production costs.”